July 01, 2020 – SAN DIEGO, California
ABM Therapeutics announced on June 22, 2020 that the first patient has been dosed in a phase I first-in-human clinical trial of their lead candidate, ABM-1310, a novel BRAF inhibitor with high solubility and brain permeability. The multicenter clinical trial is being conducted in patients with BRAF mutant advanced solid tumors, including patients with brain metastasis.
Dr. Chen Chen, founder and CEO of ABM Therapeutics, said, “Many cancer patients are affected by brain metastases, but current treatment options are limited. ABM-1310 significantly prolonged median survival time of brain metastases in preclinical models and is expected to be a new generation of BRAF inhibitors for the treatment of various malignant tumors and brain metastases.”
Dr. Qinhua Cindy Ru, managing director of CRC Oncology, stated, “We are pleased the ABM-1310 study has been able to overcome recent challenges in clinical trial conduct that is being experienced worldwide. The dosing of the first patient is a significant milestone for our collaboration with ABM, and we look forward to continuing our collaboration on the development of ABM-1310.”
For the company’s original release, please visit https://www.prnewswire.com/news-releases/abm-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-abm-1310-in-the-usa-301080914.html.
ABM-1310 is a novel BRAF inhibitor, developed by ABM Therapeutics, with high solubility and brain permeability. A phase I, first-in-human, trial to evaluate the safety and tolerability of ABM-1310 is being conducted in patients with BRAF mutant advanced solid tumors at multiple clinical sites in the U.S. More information about this study can be found on ClinicalTrials.gov: NCT04190628.
About ABM Therapeutics
ABM Therapeutics is a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, with an emphasis on brain cancer and cancer metastasis. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaborations with CROs. ABM's pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet need of treating cancer and metastases in the brain. For more information, please visit http://www.abmtx.com.
About CRC Oncology
CRC Oncology is a contract research organization (CRO) focused on reshaping the global landscape of innovative drugs and therapies for cancer treatment. CRC Oncology provides high quality development and research services by strategically driving global regulatory submissions, authoring quality eCTD dossiers, leading US clinical development, advancing quality management expertise, building and maintaining a 24/7 audit trail, providing full GxP compliance master quality management systems, and bridging global business development needs. For more information, visit www.crconc.com.